DrugDev continues to expand strong adoption of DrugDev Spark in Europe with rapid growth for site selection, activation, eConsent, LMS and global site payments solutions
Adoption of DrugDev Spark, the world’s first unified clinical operations suite, continues to escalate worldwide with strong demand in Europe and ROW for proven solutions including site selection, activation, eConsent, LMS and global site payments. To support this rapid growth, George Masoura has joined the company as Vice President, Business Development, Europe.
DrugDev’s global focus and expertise is reflected in its experience working with 85 sponsors and CROs on more than 1,800 clinical trials. With study team and site users in 60 countries, DrugDev leads the industry in geographical scale with US$2B paid to sites in 37 currencies, over 17,000 clinical trial agreement contracts successfully negotiated, a multilingual 60-person team based in London focused primarily on site selection and support, and a proprietary network of more than 75,000 investigators in 125 countries (60% ex-US) actively seeking new trial opportunities.
In addition, DrugDev is pioneering leading technologies throughout Europe and beyond, including a robust learning management system, site engagement technology, and the industry’s definitive eConsent solution (register for a European eConsent webinar on 12 April 2017 for an educational demo).
“Our roots are firmly in Europe, so on a personal level it’s rewarding to see such strong demand for using technology to improve global clinical operations throughout Europe,” said Melissa “Liss” Easy, DrugDev Founder and President, SiteStart. “When I founded the company 10 years ago in London as a network of self-selected investigators, I had no idea DrugDev would become what it is today. The unified DrugDev Spark clinical operations suite inherently eliminates geographical boundaries by creating a consistent and collaborative experience for the global study teams and site staff. I’m so grateful to our customers who have inspired us to create solutions that transform clinical trial efficiency and quality for sponsors and sites based in Europe and around the world.”
George Masoura joins DrugDev to continue building relationships with European and ROW pharmaceutical companies as global demand for proven technology solutions increases – with especially strong interest in site selection and feasibility, site activation, LMS, site payments and eConsent. See all the solutions DrugDev Spark offers at www.drugdev.com.
With over 20 years’ experience in the pharmaceutical industry, Masoura brings a wealth of specialized knowledge and skills to DrugDev’s continued expansion of its European operations. His global perspective and track record in business acquisition gained from working with many of the leading eClinical market innovators combined with expertise in digital transformation, outsourcing, business performance improvement and data governance will play a vital role in DrugDev’s future growth.
“I’m joining DrugDev at an exciting time,” said Masoura. “DrugDev Spark is an advanced technology platform its unified approach brings a paradigm shift to organisations that want to gain better control and visibility over their trial activities. We’re leading a fundamental change in the way people think of clinical trials and how the sponsors engage with sites and patients. What attracted me most is the passion DrugDev has for the challenge of improving clinical research outcomes, the will and ability to meet it, and the element of empathy it brings to clinical development. I’m proud to be part of a company that has such a remarkable ability to bring together technology assets and a clear understanding and anticipation of market needs in Europe.”
Previously Masoura was Senior Business Development Director, Informatics, at Covance, where he led strategic sales and business development activities for the Xcellerate informatics platform. He also held senior sales and marketing positions at ECLINSO LLC, unithink inc., Medidata Solutions and CRF Health, among others. As an independent consultant, he specialized in business development activities to improve the operational efficiency of pharma companies through technology adoption and process modernization.